Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation.
With greater numbers of patients surviving long-term after allogeneic stem cell transplantation (SCT), second malignancies have increasingly been recognized. Secondary solid tumors, the most prevalent second malignancies after allogeneic SCT, are reviewed with particular emphasis on recent developments in the pathogenesis, early diagnosis, and treatment of these transplant-related complications.
Hematology Transplantation, APHP Hospital Saint Louis and University Paris VII Denis Diderot, Paris, France. gerard.socie@sls.aphp.fr
Gerard
G
Socié
J Douglas
JD
Rizzo
D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008403:Mass Screening; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000517:prevention & control / Q000628:therapy*; D017410:Practice Guidelines as Topic; D017741:Survivors; D013997:Time Factors; D014184:Transplantation, Homologous